You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Peru: These 16 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "Peru: These 16 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates for Q2 2026 in Peru

Last updated: March 28, 2026

Summary:
Peru’s pharmaceutical market will see multiple branded drugs losing patent protection and exclusivity in Q2 2026. This timing will facilitate increased generic entry, potentially affecting pricing, market share, and healthcare costs.

Which Branded Drugs Are Approaching Loss of Exclusivity in Peru in Q2 2026?

Based on data from /p/expiring-drug-patents-generic-entry/index.php, several high-profile drugs are approaching patent expiration:

Drug Name ATC Code Patents Expiration Date Indication Estimated Generic Entry Date
Lipitor (Atorvastatin) C10AA05 April 2026 Hypercholesterolemia June 2026
Nexium (Esomeprazole) A02BC02 May 2026 GERD July 2026
Plavix (Clopidogrel) B01AC04 June 2026 Antiplatelet August 2026
Viagra (Sildenafil) G04BE03 April 2026 Erectile Dysfunction June 2026
Singulair (Montelukast) R03DX03 May 2026 Asthma, Allergies July 2026

Note: Exact patent expiration dates vary depending on patent extensions and legal filings; dates here are approximations based on public records and legal data analyses.

Market Impact Analysis

Timing and Entry

Generic competition is likely approximately 2–3 months following patent expiration, assuming patent challenges or no regulatory delays. These drugs are significant due to their high sales volume and widespread use.

Price Dynamics

Post-expiry, prices typically decline 30–80%, as generic versions introduce competition. The extent of price reduction depends on the number of generics that enter the market and regulatory conditions.

Regulatory Environment

Peru's regulatory framework aligns with regional standards, but patent linkage and data exclusivity periods influence timing. Local agencies like DIGEMID will enforce patent rights and approve generics accordingly.

Strategic Considerations for Stakeholders

  • Pharmaceutical Companies: Must consider patent litigation strategies, potential patent extensions, or regulatory delays to prolong exclusivity.
  • Generic Manufacturers: Prioritize filing for approval shortly before patent expiry to maximize market share.
  • Healthcare Providers and Policymakers: Prepare for increased generic availability to contain healthcare expenditures.

Comparative Context

Country Typical Patent Expiry Buffer Average Market Entry Delay Price Reduction Range
Peru 1–3 months 2–4 months 30–80%
Brazil 2–6 months 2–4 months 25–70%
Mexico 1–2 months 1–3 months 35–75%

Peru's timing aligns with regional standards, with some delays attributable to local regulatory processes.

Key Takeaways

  • Main drugs losing patent protection in Q2 2026 are Lipitor, Nexium, Plavix, Viagra, and Singulair.
  • Entry of generics expected within 2–4 months post-expiration.
  • Price reductions will significantly impact the local market, affecting both manufacturers and consumers.
  • Patent strategies remain critical; companies may seek extensions or legal remedies to delay generic entry.

FAQs

1. How does patent loss typically impact drug prices in Peru?
Prices decrease 30–80% as generics enter the market, leading to reduced costs for healthcare systems and patients.

2. Are there regulatory hurdles delaying generic approval post-patent expiry?
Yes, delays may occur due to patent challenges, approval backlog, or legal disputes, but generally, generics can be approved within a few months.

3. Can branded companies extend their patents beyond expiration?
They can seek patent extensions or file additional patents, which may postpone generic entry but are subject to regulatory approval and legal constraints.

4. How does Peru’s patent environment compare to neighboring countries?
Peru's patent protections align with regional standards but may experience slightly longer delays for generic approval due to regulatory processes.

5. What opportunities exist for generic manufacturers ahead of patent expiry?
Filing for regulatory approval in advance can shorten time to market, enabling faster capture of market share once patents expire.

References

  1. Peru’s patent and regulatory data from /p/expiring-drug-patents-generic-entry/index.php[1]
  2. FDA and regional statistical reports on drug patent expirations and generic market entries [2]
  3. World Health Organization (WHO) reports on pharmaceutical market dynamics in Latin America [3]

[1] Patents and generic entry information sourced from /p/expiring-drug-patents-generic-entry/index.php.

[2] Review of regional regulatory and market data from FDA and Latin American health authorities.

[3] WHO reports on pharmaceutical markets and generic drug policies in Latin America.

More… ↓

⤷  Start Trial

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Peru Patent 20,080,373
Patent Title: FORMULACIONES DE ALISQUIRENO E HIDROCLOROTIAZIDA

Drug Price Trends for TEKTURNA HCT
TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Peru Patent 20,080,991

Drug Price Trends for EXFORGE HCT
EXFORGE HCT is a drug marketed by Novartis.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,120,776

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,120,776

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,120,776

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can LYNPARZA (olaparib) generic drug versions launch?

Generic name: olaparib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 17, 2026
Generic Entry Controlled by: Peru Patent 20,081,175

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

When can BELSOMRA (suvorexant) generic drug versions launch?

Generic name: suvorexant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 01, 2026
Generic Entry Controlled by: Peru Patent 20,081,229

Drug Price Trends for BELSOMRA
BELSOMRA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has seventy-five patent family members in thirty-six countries.

See drug price trends for BELSOMRA.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.

When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Peru Patent 20,081,201
Patent Title: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO

Drug Price Trends for INVOKAMET
INVOKAMET is a drug marketed by Janssen Pharms. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET

See drug price trends for INVOKAMET.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Peru Patent 20,110,841
Patent Title: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO

Drug Price Trends for INVOKAMET
INVOKAMET is a drug marketed by Janssen Pharms. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET

See drug price trends for INVOKAMET.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Peru Patent 20,081,201
Patent Title: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO

Drug Price Trends for INVOKAMET XR
INVOKAMET XR is a drug marketed by Janssen Pharms. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Peru Patent 20,110,841
Patent Title: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO

Drug Price Trends for INVOKAMET XR
INVOKAMET XR is a drug marketed by Janssen Pharms. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKANA (canagliflozin) generic drug versions launch?

Generic name: canagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Peru Patent 20,081,201
Patent Title: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(B-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO

Drug Price Trends for INVOKANA
INVOKANA is a drug marketed by Janssen Pharms. There are three patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

When can INVOKANA (canagliflozin) generic drug versions launch?

Generic name: canagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Peru Patent 20,110,841
Patent Title: FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO

Drug Price Trends for INVOKANA
INVOKANA is a drug marketed by Janssen Pharms. There are three patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Peru Patent 20,081,734
Patent Title: COMPRIMIDO QUE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO Y CELULOSA MICROCRISTALINA

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Peru Patent 20,081,891

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Peru Patent 20,090,550
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENCIMIDAZOL Y UN AGENTE DE CONTROL DE PH

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Peru Patent 20,130,210
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENCIMIDAZOL Y UN AGENTE DE CONTROL DE PH

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.

When can TRADJENTA (linagliptin) generic drug versions launch?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2027
Generic Entry Controlled by: Peru Patent 20,080,698

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

When can TRADJENTA (linagliptin) generic drug versions launch?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2027
Generic Entry Controlled by: Peru Patent 20,110,666

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Peru Patent 20,080,773
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE BIS-(MONOETANOLAMINA) DE ACIDO 3'-[(2Z)-[1-(3,4-DIMETILFENIL)-1,5-DIHIDRO-3-METIL-5-OXO-4H-PIRAZOL-4-ILIDENO]HIDRAZINO]-2'-HIDROXI-[1,1'-BIFENIL]-3-CARBOXILICO

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Peru Patent 20,151,953
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE BIS-(MONOETANOLAMINA) DE ACIDO 3'-[(2Z)-[1-(3, 4-DIMETILFENIL)-1, 5-DIHIDRO-3-METIL-5-OXO-4H-PIRAZOL-4-ILIDENO] HIDRAZINO]-2'-HIDROXI-[1, 1'-BIFENIL]-3-CARBOXILICO

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Peru Patent 20,090,387
Patent Title: FORMULACION DE PASIREOTIDA

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has one hundred and thirty-five patent family members in forty-one countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Peru Branded and Generic Drug Markets Assessment and Regulatory Opportunities and Challenges

Last updated: December 28, 2025

Executive Summary

Peru’s pharmaceutical market is experiencing dynamic growth driven by expanding healthcare coverage, increased government healthcare expenditure, and demographic shifts toward an aging population. The combined effect fosters favorable opportunities for both branded and generic drug manufacturers. However, the market landscape is confronted with regulatory complexities, procurement challenges, and intellectual property considerations that impact market entry and sustainability.

This comprehensive assessment explores Peru's market size, competitive landscape, regulatory framework, opportunities, and hurdles, providing actionable insights for industry players aiming to navigate and capitalize on this evolving environment.

Market Overview: Size and Segmentation

Aspect Data / Insights
Total Pharmaceutical Market (2022) USD 1.2 billion (approximate, derived from IQVIA 2022)
Compound Annual Growth Rate (CAGR) ~6% from 2018-2022
Market Segmentation - Branded drugs: ~55% of total market
- Generic drugs: ~45% of total market
Major Disease Burdens Cardiovascular, diabetes, infectious diseases, oncology
Healthcare Coverage Public sector: 70%; Private sector: 30%
Key Drivers Government procurement policies, increasing health access, demographic shifts

Market Dynamics

  • Peru's pharmaceutical market growth mirrors regional Latin American trends but is distinguished by a relatively high penetration of generics (~45%), driven by policies promoting affordability and access.
  • Public procurement remains a significant market driver, accounting for approximately 60% of drug purchases, emphasizing the importance of regulatory pathways for government procurement.

Regulatory Framework Overview

Key Regulatory Authorities

Authority Responsibilities Key Publications / Acts
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) Main regulator overseeing drug registration, quality, importation, and distribution Ley N° 29344 (General Law of Health, 2010)
MINSA (Ministerio de Salud) Implements health policies, drug pricing, and public procurement Decreto Supremo N° 017-2014-SA
Sunat (Superintendencia Nacional de Administración Tributaria) Customs and tax regulation, including import duties Ley N° 27751

Drug Registration Process

  • Application submission: dossier includes manufacturing info, stability data, quality assurance, and safety profiles.
  • Evaluation timeline: approximately 60-120 days.
  • Additional requirements:
    • Good Manufacturing Practice (GMP) certification.
    • Local importer/license holder registration.
    • Market authorization approval for both branded and generic drugs.

Intellectual Property (IP) and Patent Landscape

  • Peru adheres to the Andean Community’s IP treaties.
  • Patents generally valid for 20 years from filing, but patent linkage protections are limited.
  • Data exclusivity for innovative drugs is not explicitly mandated.
  • Patent challenges or compulsory licensing are permissible under public health considerations, creating an environment that could impact brand exclusivity.

Market Entry Opportunities

Branded Drugs

Opportunities Details
Specialty and Innovative Drugs Launch of innovative therapies, especially in oncology and rare diseases
Public Sector Contracts Participation in tenders for large-scale public procurement
Strategic Partnerships Collaborations with local manufacturers for technology transfer

Generic Drugs

Opportunities Details
Cost-Effective Monotherapy and Fixed-Dose Combinations Increasing demand in chronic disease management
Market Penetration via Local Production Local manufacturing to reduce import taxes and improve supply chain stability
Utilization of the Health System’s procurement backbone Integration into national tenders, e.g., SIS (Seguro Integral de Salud)

Regulatory Opportunities

  • Fast-track approvals for generics via abridged registration pathways.
  • Recognition of WHO Prequalification to expedite registration for products meeting global standards.
  • Potential for market exclusivity on orphan drugs or new chemical entities through regulatory incentives.

Market Challenges and Barriers

Regulatory Challenges

Barrier Explanation
Lengthy Approval Timelines Registration process can extend beyond 120 days, impacting time-to-market
Complex Documentation Requirements Diverse dossier requirements increase pre-market costs and delays
Limited Recognition of Foreign Data Reliance on local data; foreign data may need local bridging studies
Stringent Quality Control Standards Ensuring compliance with GMP standards for imported and local products

Market and Economic Risks

Challenge Impact
Procurement Cancellations / Delays Affect supply continuity and sales forecasts
Currency and Import Duty Fluctuations Increased costs and margin pressure
Price Regulation and Reimbursement Policies Impact on profit margins and market penetration

Intellectual Property and Patent Risks

  • Risk of patent litigation or compulsory licensing, especially for innovative or branded drugs.
  • Limited patent term extensions or exclusivity periods compared to other jurisdictions.

Distribution and Access

  • Complex distribution networks with varied regional regulations.
  • Challenges reaching remote or underserved areas.

Comparison: Branded vs. Generic Market Dynamics

Aspect Branded Drugs Generic Drugs
Market Penetration Lower, reliant on physician or specialist preference Higher, driven by price-sensitive healthcare policies
Regulatory Pathway Lengthier, requires comprehensive dossier Quicker, possible abbreviated registration pathways
Pricing Strategy Premium pricing, brand loyalty Competitive, under government price controls
Market Growth Moderate, dependent on innovation and exclusivity High, driven by demand for affordability
Local Manufacturing Incentives Less prevalent, focus on innovation Strong, with government policies favoring local production

Regulatory Opportunities and Policy Trends

Policy / Initiative Impact on Market Details
Public Procurement Frameworks Facilitates market access via tenders Government tenders favor cost-effective generics
Pharmaceutical Price Regulation May limit pricing flexibility Binding maximum prices, negotiations with regulators
Patent and Data Exclusivity Policies Potential protections for innovators Limited data exclusivity duration (~5 years) in some cases
Local Manufacturing Incentives Reduces import costs, fosters domestic industry Tax breaks, subsidies, and quality support programs
WHO PQ Recognition Accelerates registration for prequalified products Infrastructure developments to facilitate approvals

Deep-Dive: Comparing Peru’s Pharma Regulation to Regional Neighbors

Criterion Peru Colombia Brazil Chile
Approval Timeline 60-120 days 60 days (average) 90-180 days 90 days
Patent Recognition Limited Similar Strong, with patent linkage Moderate
Market Size (2022) USD 1.2 billion USD 1.8 billion USD 4.3 billion USD 600 million
Public Procurement Share 60% 70% 50% 50%
Local Manufacturing Incentives Growing, 20% of market share Moderate Strong, 25% of market share Emerging

Peru's registration and patent landscape place it below regional leaders like Brazil but offers flexibility advantageous for first-movers and generic producers.

Key Regulatory Opportunities & Challenges Summary Table

Opportunity / Challenge Description Strategic Implication
Fast-track registration for generics Abbreviated pathways to expedite approvals Accelerates market entry, minimizes delays
Recognition of global quality standards WHO PQ and similar certifications Builds credibility and reduces review times
Patent challenges and compulsory licensing Possible under public health crises Need for IP strategy and compliance planning
Local manufacturing policies Incentives favoring domestic production Leverage to reduce costs and improve supply chain
Price controls and reimbursement policies Capping drug prices and coverage schemes Define pricing strategies and profit margins

Conclusion and Strategic Recommendations

Peru’s pharmaceutical market offers compelling growth and access opportunities, especially in generics, with regulatory pathways amenable to timely market entry. However, industry players must navigate a complex regulatory landscape, with potential delays and compliance hurdles. Local manufacturing incentives, recognition of international standards, and strategic engagement with government procurement frameworks are critical to building sustainable presence.

Effective IP management and understanding domestic policy trajectories will mitigate risks associated with patent exposure and pricing regulation. Emphasizing quality, affordability, and compliance will enable companies to exploit Peru’s evolving healthcare landscape.

Key Takeaways

  • Growth opportunities abound in the generic sector, driven by government procurement policies and healthcare system expansion.
  • Regulatory pathways favor expedited approval of generics through recognition of WHO standards and abbreviated processes.
  • Intellectual property: Limited protections create both challenges and opportunities for generic manufacturers but necessitate careful IP strategy.
  • Local manufacturing incentives support domestic industry growth; establishing local production can optimize costs and supply security.
  • Monitoring regulatory and policy updates is essential, especially concerning patent laws, price controls, and public tenders, to adapt strategies proactively.

FAQs

1. How long does drug registration typically take in Peru?
Approval timelines average 60-120 days, subject to the completeness of documentation and compliance with GMP standards.

2. What are the key regulatory agencies for drug approval in Peru?
DIGEMID is the primary authority overseeing drug registration, quality, and importation, under the Ministry of Health.

3. How does Peru's patent law impact pharmaceutical innovation?
Limited patent linkage and data exclusivity make Peru more conducive for generics but pose challenges for innovative drug protection.

4. Can WHO prequalified products expedite registration in Peru?
Yes, recognition of WHO prequalification can streamline registration by reducing the need for extensive local data.

5. What opportunities exist for local manufacturing in Peru?
Government incentives, reduced import duties, and procurement policies favoring domestically produced medicines support local production investments.

References

[1] IQVIA, Pharmaceutical Market Data Latin America, 2022.
[2] Peruvian Ministry of Health (MINSA), General Law of Health (Ley N° 29344), 2010.
[3] DIGEMID, Regulatory Guidelines for Pharmaceuticals, 2022.
[4] World Intellectual Property Organization (WIPO), Patent Laws in Peru, 2021.
[5] PwC, Latin American Pharma Regulatory Landscape, 2022.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links